don’t know if it helps, but here is the answer i received

New Post Public Reply Private Reply Replies (4) Message Board
turn_around
1,138
don’t know if it helps, but here is the answer i received from todd on 11/04
i would say they are gagged for unknown reason.

Hello xxx

I hope you are well.

My hope & expectations are we will be able to discuss corporate actions shortly. But is shortly tomorrow – next week – 3 weeks - more??? That I don’t know, & even if I did I couldn’t tell you.

What I do know is since SARS-CoV-2 came into our lives last February/March 2020, this company has had several significant issues to deal with.
I can tell you President & CEO Joe Moscato & our Management Team want nothing more than to address the shareholders, & a press release will be put out as soon as it is possible to do so.

Have events gone as planned? No… That said, we are not stopping & we are working to get things done, & announced as soon as possible.

I also add;
The Corporate Structure, Valuations & Listing details of NuGenerex Immuno-Oncology (NGIO) are expected soon.
All corporate filings for NuGenerex Immuno-Oncology Inc. (NGIO) are updated & filed as they happen. https://www.sec.gov/cgi-bin/browse-edgar?CIK=1804585

NUGX - are not the (NuGenerex Immuno-Oncology (NGIO)) shares that will be listed shortly by our company.
Those are the dividend shares that someone outside the company has listed to trade.

I politely reiterate, the activities surrounding the trading of NUGX is not from our company & I am not able to advise you on this trading.

Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are the company, not the financial institution who facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company’s common stock in the context of the stock dividend.

For the sake of history since Jan 2017 when President & CEO Joe Moscato & his new team took over Generex Biotechnology Corp. & brought back from more or less being a dead corporation, there have been 5 corporate stock actions.

An original 1000 to 1 rollback of GNBT stock (Mach 2017)
1 share of (GNBT) stock got you 20 additional shares of (GNBT) stock Dec 3rd, 2018
5 shares of (GNBT) stock got you 2 additional shares of (GNBT) stock Feb 25th, 2020.

Also 2 sets of shares dividends of NuGenerex Immuno-Oncology / Formally Antigen Express - (not yet a publicly trading company).
Shares that were settled in accounts at the aforementioned dates are entitled to shares of: NuGenerex Immuno-Oncology (Formally named Antigen Express)
Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology shares.

4 (GNBT) shares got you 1 dividend share of (NGIO) Feb 26th, 2019 - NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet.
5 (GNBT) shares got you 2 dividend shares of (NGIO) Feb 25th, 2020 - NuGenerex Immuno-Oncology (NGIO) does not trade publicly yet.

No shares that are tradeable public shares of (NGIO) NuGenerex Immuno-Oncology have been sent out.
The corporate structure is not finalized, the trading platform is not finalized.
Yes, NuGenerex Immuno-Oncology (Formally named Antigen Express) is considered a public company today but, no publicly listed shares have been issued from the company.

All shareholders of record will receive their dividends.

We work to get Generex Biotechnology Corp. back to the Nasdaq. Then firms, institutions, and the larger investor base that don’t buy OTC stocks will become interested in what we are doing.
That’s why we go to such lengths to file S-1’s so we can raise institutional money leading us to become Nasdaq compliant.
Why? How? They will buy stock & hold it on their books, and write research reports, and have us as presenters at their Pharma Investment Conferences and that is how to build a company for years, decades of advancing success.

That’s what is being built, this is what Joe Moscato & our team is putting together.

Our President & Chief Executive Officer Joseph Moscato will continue to update shareholder as to pending acquisitions and previously discussed corporate actions.
We will continue to communicate with shareholders our company’s operational progress, strategic plans, and M&A activities as soon as they take place.

Information of the two NGIO share dividends to (GNBT) shareholders.
Shares that were settled in (OTCQB:GNBT) accounts at the aforementioned dates are entitled to shares of NuGenerex Immuno-Oncology (Formally named Antigen Express)
Two separate share dividends were awarded to shareholders of Generex Biotechnology Corp. (OTCQB:GNBT) for NuGenerex Immuno-Oncology.
4 to 1 dividend from Feb 26th, 2019
5 to 2 dividends from Feb 25th, 2020
NuGenerex Immuno-Oncology (Formally named Antigen Express) (NGIO) shares do not trade yet.

Respectfully, I tell everyone I talk to, or email, regarding all dividend related questions that we are the company, not the financial institution that facilitates these actions, and not the regulator agent who oversees this type of activity. This email does not constitute legal advice. Investors are encouraged to solicit independent legal advice and to consult their independent investment brokerage firms as to record, payment, and ex-dividend dates and the application thereof to trades in the Company’s common stock in the context of the stock dividend.

Keep in mind, the NGIO stock does not trade yet.

Transfer Agent (NEW)
https://www.stctransfer.com/
Securities Transfer Corporation
Plano, Texas

2901 Dallas Pkwy Suite 380,
Plano, TX 75093,
United States
1 469 633 0101

If you would like to discuss anything further please don’t hesitate to call me.
1 800 391 6755 x 222

Regards,
Todd

Todd Falls
Generex Biotechnology Corporation
Communication Director & Investor Relations Officer
USA Headquarters:
Generex Biotechnology, Inc.
10102 USA Today Way
Miramar, FL 33025
Direct Office:1-800-391-6755 - 222
phone: 416.364.2551 ext. 222
e-mail: tfalls@nugenerex.com
www.generex.com

Toronto Location:
4145 North Service Road, Suite 200
Burlington, Ontario
Canada L7L 6A3

Generex Biotechnology Subsidiaries:
AntigenExpress, Inc.
www.antigenexpress.com
Hema Diagnostics, Inc.
www.hemadiagnosticsystems.com

This electronic mail (e-mail) is intended solely for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable federal and international laws. If the reader of this communication is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this e-mail is strictly prohibited. If you have received this communication in error, please do not print, copy, re-transmit, disseminate, or otherwise use any of the information contained herein, and notify the sender immediately by replying to the e-mail address above. While messages are confidential, authorized management, legal and compliance personnel may review electronic messages. Electronic messages are also retained and would be provided upon request to an authorized regulatory body.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 44

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 148

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 134

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading
Painter's Accessory Aims to Revolutionize Convenience

Updated Category News Views 64

Crafty New Invention Targets Painters' Ease Ever find yourself tangled in paintbrushes and rollers while trying to get that perfect coat on the wall? Well, a painter from Bracebridge, Ontario, has had it with the struggle and is looking to stir the pot with their latest invention, the NU LIFE LINER. It's sleek, it's practical, and it's aimed at flipping the painting game...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 124

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 120

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 270

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 102

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Starbucks Earnings Anticipation: Growth and Challenges Ahead

Updated Category News Views 152

Starbucks Earnings Preview Starbucks (NASDAQ: SBUX) is set to announce its quarterly earnings shortly. Investors are keenly awaiting the report, reflecting hopes for positive outcomes and growth perspectives. The anticipation surrounding this announcement includes significant insights that could shape investor sentiment. Expected Earnings Report Analysts have projected...

Continue Reading
Understanding the Current Options Trends of T-Mobile US

Updated Category News Views 192

Insights into T-Mobile US Options Activity Recently, T-Mobile US has witnessed a stark shift in options trading, driven by significant market movements. A detailed examination of the options history for T-Mobile US (NASDAQ: TMUS) has unveiled a string of unusual trades that indicate a complex trading atmosphere. Delving deeper, our analysis shows that about 41% of traders...

Continue Reading
Arteris, Inc. Boosts Team with New Inducement Stock Awards

Updated Category News Views 282

Arteris, Inc. Announces Substantial Inducement Stock Grants Arteris, Inc. (Nasdaq: AIP), a prominent provider of system IP for accelerating semiconductor innovation, recently revealed an exciting development regarding its workforce expansion. The company has made the decision to grant a total of 109,000 restricted stock units (RSUs) to four newly hired employees as part...

Continue Reading
Enhanced Drill Insights from Freeman Gold's Latest Project

Updated Category News Views 217

Freeman Gold Unveils Significant Drill Results Freeman Gold Corp. (TSXV: FMAN, OTCQB: FMANF) has recently shared exciting outcomes from its expanded drilling initiative, which aims to enhance the Lemhi Gold Project. The results of the three drill holes from the southern segment of their 2025 drilling program indicate potential for substantial gold deposits, further...

Continue Reading
Exploring the Growth of the Paper and Paperboard Market

Updated Category News Views 146

Forecasting the Future of Paper and Paperboard Packaging The global paper and paperboard container and packaging market is on track to experience remarkable growth, with estimated revenues soaring by USD 59.15 billion during the forecast period. The projected CAGR for this timeframe stands at 4.39%, fueled by a surge in the demand for specialized containers and innovative...

Continue Reading